Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECISE Trial: Chiglitazar Sodium in Prediabetes
NCT07558525Not yet recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in prediabetes comparing Chiglitazar Sodium + Lifestyle Intervention with Placebo + Lifestyle Intervention (2 arms). Primary endpoint: Reversion Rate to Normal Glucose Metabolism at 64 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
chiglitazar
03
Conditions
prediabetes
Beyond the preview
Go deeper on NCT07558525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07558525.